2014 first-quarter revenues
Bezons, April 28th, 2014 - 5:45pm - RIBER, the global leader for molecular beam epitaxy (MBE), recorded €1.8 million in revenues for the first quarter of 2013, compared with €2.7 million for the first quarter of 2013.
| At March 31st (€'000,000) | 2014 | 2013 | Change |
| Systems | 0.0 | 0.9 | -95% |
| Services and accessories | 1.5 | 1.4 | +9% |
| Cells and sources | 0.3 | 0.4 | -41% |
| Total reported revenues | 1.8 | 2.7 | -34% |
| Systems order book | 4.5 | 13.4 | -66% |
| Services and accessories order book | 2.0 | 1.1 | +82% |
| Cells and sources order book | 0.2 | 0.1 | +26% |
| Total order book | 6.6 | 14.6 | -55% |
MBE systems revenues
Whilst no revenues were recorded for MBE systems during the first quarter of 2014, this reflects the production cycle for systems that have been ordered for 2014 and is not an indication of the company's performance over the full year. During the quarter, RIBER produced three research systems ordered for a total of €3 million; for contractual reasons, these systems will only be delivered and invoiced in the second and third quarters of 2014.
Services, accessories and cells revenues
The MBE services and accessories business is growing, with year-on-year growth in terms of both its revenues and its order book. The increase in sales has been driven by the good performance with research markets (in which RIBER benefits from its large installed base), while industrial markets have remained flat.
On the OLED flat screen, RIBER is actively preparing for the next waves of investments by further strengthening its research and development efforts and its technical and commercial proximity with leading players in Asia.
Outlook
As announced on January 23rd, 2014, during the first quarter RIBER recorded a research MBE system order in the United States. The order book represented €6.6 million at March 31st, 2014. Since then, an order has been placed for two major research MBE systems in Asia (announced on April 15th).
Next date: 2013 annual report to be published on April 29th, 2014 (general meeting on Tuesday June 3rd, 2014)
About RIBER:
Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, from new information technologies to OLED flat screens and new generation solar cells.
The Riber Group recorded €23.5 million in revenues for 2013, with 109 employees at the end of 2013. The company is ISO9001 certified. Riber is listed on NYSE-Euronext Paris, Compartment "C", and is part of the CAC Small, CAC Mid & Small, CAC Technology and CAC T. HARD. & EQ indices. Riber is one of the best-rated companies in the Gaïa-index, the leading SRI index for French mid-caps. Riber is eligible for SME share-based savings schemes.
ISIN: FR0000075954 - RIB
Reuters: RIBE.PA
Bloomberg: RIB: FP
OSEO-approved innovative company
| RIBER Olivier Handschumacher tel: +33 1 39 96 65 00 invest@riber.com | CALYPTUS Cyril Combe tel: +33 1 53 65 68 68 cyril.combe@calyptus.net |
www.riber.com
